PASTIC Dspace Repository

Therapeutic effect of gefitinib on patients with advanced EGFRmutation NSCLC

Show simple item record

dc.contributor.author Xu, Ailing
dc.contributor.author Yan, Haixia
dc.contributor.author Bu, Tongliang
dc.date.accessioned 2022-10-20T10:15:17Z
dc.date.available 2022-10-20T10:15:17Z
dc.date.issued 2021-01-16
dc.identifier.issn 1011-601X
dc.identifier.uri http://142.54.178.187:9060/xmlui/handle/123456789/13505
dc.description.abstract This study aims to study the role of gefitinib on patients with advanced EGFR-mutation NSCLC (Non-Small Cell Lung Cancer). Totally 115 patients with advanced EGFR-mutation NSCLC treated in our hospital were enrolled as research objects. They were randomly divided into control group (n=57) applied with cisplatin + pemetrexed and experimental group (n=58) subject to gefitinib+ cisplatin + pemetrexed, both groups were applied with treatment for 4 cycles. Clinical efficacy: The disease control rate (DCR) was 72.41% in the experimental group, which was higher than that of the control group (54.39%, p<0.05); Serum CEA, CYFRA21-1, MMP-9 levels: after 2 and 4 cycles of treatment, serum CEA, CYFRA21-1, and MMP-9 levels were lower in the experimental group (p<0.05); Immune function: after 2 and 4 cycles of treatment, Th1 cells and Th1/Th2 cell levels were higher in the experimental group, while Th2 cell level was higher in the control group (p<0.05); Angiogenesis related indicators: the levels of VEGF, HIF-1α and sCD105 were lower in the experimental group after 2 and 4 cycles of treatment (p<0.05); (5) Adverse reactions: After 2 and 4 cycles of treatment, the levels of VEGF, HIF-1α, and sCD105 were lower in the experimental group (p<0.05). The application of gefitinib in patients with advanced EGFR-mutation NSCLC can help down-regulate CEA, CYFRA21-1, and MMP-9 levels, inhibit angiopoiesis, enhance immune function, and increase disease control rate. en_US
dc.language.iso en en_US
dc.publisher Karachi: Faculty of Pharmacy & Pharmaceutical Sciecnes, University of Karachi en_US
dc.subject NSCLC en_US
dc.subject EGFR en_US
dc.subject gefitinib en_US
dc.subject MMP-9 en_US
dc.subject CYFRA21-1 en_US
dc.subject immune function en_US
dc.title Therapeutic effect of gefitinib on patients with advanced EGFRmutation NSCLC en_US
dc.type Article en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account